Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate for Glucocorticoid-Induced Bone Loss
NCT00480766Phase 3Completed
- Sponsor
- Organon & Co.
- Start
- Jul 2001
- Primary completion
- Aug 2003
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in glucocorticoid-induced osteoporosis (GIOP) comparing Alendronate Sodium with Placebo (2 arms). Primary endpoint: Percentage Change in Bone Mineral Density at 12 months. Started Jul 2001; status: completed.
02
Drugs
alendronate
03
Conditions
glucocorticoid-induced osteoporosis (GIOP)
Beyond the preview
Go deeper on NCT00480766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00480766.